Where Wegovy Is Made and How It Reaches You in the UK

Step 1: where semaglutide actually comes from

Novo Nordisk, founded in Denmark in 1923, manufactures Wegovy at its sites in Kalundborg, Denmark, which is one of the largest pharmaceutical production complexes in the world. Additional manufacturing capacity for semaglutide has been developed in Clayton, North Carolina, in the United States, as global demand grew sharply after Wegovy received approvals in multiple countries. The Kalundborg site handles both the synthesis of the active molecule and the filling of finished pens.

Semaglutide itself is not extracted from a plant or mineral. It is built through a carefully controlled biological and chemical process: microbial fermentation produces precursor peptides, which are then modified in a series of chemical steps to create the final molecule. That molecule is then formulated with excipients, filled into cartridges, and assembled into the pre-filled injection pens that patients use. The process is lengthy. Industry figures suggest it can take around twelve months from starting materials to finished, tested product — one reason that supply shortages, when they occurred, proved difficult to resolve quickly. You can read more about how Wegovy is manufactured in detail if you want the chemistry explained.

For the UK market specifically, finished product batches are released only after quality testing that meets MHRA requirements. The medicine enters the UK through Novo Nordisk's authorised distribution network, which means it reaches pharmacies and patients via a traceable, regulated chain.

Step 2: how it moves through the UK supply chain

Once batches are released for the UK, distribution moves through Novo Nordisk's licensed wholesale arrangements. At this stage the medicine is subject to the Human Medicines Regulations 2012, which govern who can hold, supply and dispense prescription-only medicines. Pharmacies that dispense Wegovy must be registered with the General Pharmaceutical Council (GPhC); you can verify any pharmacy at the GPhC online register.

At nume, our GPhC-registered pharmacy (registration number 9012878) sources Wegovy exclusively through this licensed UK supply chain, with an authorised Novo Nordisk supplier relationship. That traceability matters: a pen that has not come through the regulated supply chain carries real risk, including the possibility that it was stored incorrectly, is counterfeit, or contains something other than semaglutide. The MHRA has repeatedly warned about fake weight-loss pens sold through social media and unofficial websites, and the risks are serious, fake pens have been found to contain insulin. If you are thinking about the broader cost picture, our Wegovy pricing guide covers what legitimate private supply typically costs in the UK and what that price should include.

Wegovy must be kept refrigerated between 2°C and 8°C throughout the supply chain. Breaks in that cold chain (even brief ones during transit) can degrade the medicine. Dispensing through a registered pharmacy with proper cold-chain logistics is not a formality; it is what protects the product you actually inject.

Step 3: what arrives when it is dispensed to you

After a prescriber approves a patient's consultation, the pen is dispensed from the pharmacy, packed in a cool-lined, plain unbranded box, and collected by DPD. You will receive a tracking notification so you know exactly when to expect it. The pen itself is a pre-filled, ready-to-use device, there is no drawing up of liquid, no separate vial. Inside the box you will also find the Patient Information Leaflet, which is the document to read for storage instructions, missed-dose guidance and the full list of side effects. Our prescribers ask patients to read it before their first injection.

The question of where Wegovy comes from is also connected to a broader question: who developed semaglutide and why it works the way it does. That page covers Novo Nordisk's history with GLP-1 research if you are curious about the science behind the molecule. For a broader overview of the medicine itself, the Wegovy treatment page is a good starting point.

Manufacturing origin and what it means for safety and quality

Knowing where Wegovy is made is not just a trivia question. It connects directly to questions of quality, consistency and safety. Because Novo Nordisk manufactures semaglutide at regulated GMP (Good Manufacturing Practice) facilities, every pen that leaves the factory has been produced under documented conditions that regulators can inspect and audit. The MHRA can (and does) visit or audit manufacturing sites for medicines sold in the UK. That oversight does not exist for unregulated sources.

Semaglutide is also used in Ozempic, Novo Nordisk's injection licensed for type 2 diabetes, and in Rybelsus, an oral tablet for the same indication. The molecule is the same; the licensed indication, dose and formulation differ. In June 2026, the MHRA approved Wegovy tablets (oral semaglutide, 25mg maintenance dose) as the first oral GLP-1 medicine licensed in the UK for weight management, another Novo Nordisk product from the same manufacturing base. If you want to understand how oral and injectable semaglutide compare, the semaglutide overview on this site covers both formats. There is also a detailed look at how semaglutide is synthesised if you want to go further into the science.

The short answer for anyone asking where semaglutide is made: Denmark primarily, with US capacity added as demand grew. The answer for anyone considering treatment: the route into genuine supply is through a registered prescriber and a GPhC-registered pharmacy, not a social media seller offering pens without a clinical assessment behind them. If you would like to find out whether Wegovy is clinically suitable for you, our prescribers are available to review your consultation the same day.